Corient Private Wealth LP Buys Shares of 39,081 TG Therapeutics, Inc. $TGTX

Corient Private Wealth LP bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX) during the 2nd quarter, Holdings Channel reports. The fund bought 39,081 shares of the biopharmaceutical company’s stock, valued at approximately $2,147,000.

Several other institutional investors also recently modified their holdings of the business. Pingora Partners LLC acquired a new position in TG Therapeutics in the second quarter valued at approximately $121,000. Bank of America Corp DE bought a new position in TG Therapeutics in the second quarter valued at approximately $71,960,000. Odyssean LLC grew its holdings in TG Therapeutics by 107.5% during the 2nd quarter. Odyssean LLC now owns 31,652 shares of the biopharmaceutical company’s stock worth $1,739,000 after acquiring an additional 16,398 shares during the period. Man Group plc acquired a new stake in TG Therapeutics during the 2nd quarter worth $7,273,000. Finally, Jupiter Topco LLC bought a new stake in shares of TG Therapeutics during the 2nd quarter valued at $5,319,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

TG Therapeutics Stock Up 1.4%

Shares of NASDAQ:TGTX opened at $56.90 on Thursday. TG Therapeutics, Inc. has a 52 week low of $26.76 and a 52 week high of $59.30. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.72 and a current ratio of 4.27. The company has a market capitalization of $8.71 billion, a PE ratio of 20.77, a PEG ratio of 2.40 and a beta of 1.67. The company has a 50 day moving average price of $53.48 and a two-hundred day moving average price of $42.48.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). The firm had revenue of $240.34 million for the quarter, compared to the consensus estimate of $229.77 million. TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%.The company’s revenue for the quarter was up 70.2% compared to the same quarter last year. During the same period in the prior year, the business earned $0.17 earnings per share. Analysts forecast that TG Therapeutics, Inc. will post 0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

TGTX has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $78.00 price target on shares of TG Therapeutics in a research report on Tuesday. Bank of America upped their price objective on TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a report on Tuesday, July 7th. B. Riley Financial upped their price objective on TG Therapeutics from $55.00 to $86.00 and gave the company a “buy” rating in a report on Monday, July 27th. Weiss Ratings reissued a “hold (c+)” rating on shares of TG Therapeutics in a research note on Wednesday, July 29th. Finally, Zacks Research upgraded TG Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, June 1st. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $63.00.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.